Antileukotrienes improve naso‐ocular symptoms and biomarkers in patients with NARES and asthma

The aim of our study was to analyze the montelukast effectiveness in improving oculonasal symptoms, patient‐reported outcomes (PROs), and eosinophilic biomarkers in patients with nonallergic rhinitis eosinophilic syndrome (NARES).

[1]  J. Mullol,et al.  Lack of long‐term add‐on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps , 2018, The Laryngoscope.

[2]  W. Fokkens,et al.  Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions , 2018, PloS one.

[3]  J. Bousquet,et al.  Non‐allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology , 2017, Allergy.

[4]  J. Bousquet,et al.  EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. , 2017, Rhinology.

[5]  G. Paludetti,et al.  Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? , 2017, International forum of allergy & rhinology.

[6]  N. Quaranta,et al.  Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach , 2017, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[7]  A. Boner,et al.  Effect of montelukast on markers of airway remodeling in children with asthma. , 2016, Allergy and asthma proceedings.

[8]  A. Poscia,et al.  Radiofrequency volumetric inferior turbinate reduction: long-term clinical results , 2016, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[9]  A. Perić,et al.  Nonselective chemokine levels in nasal secretions of patients with perennial nonallergic and allergic rhinitis , 2016, International forum of allergy & rhinology.

[10]  Raveendhara R. Bannuru,et al.  Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. , 2015, Annals of internal medicine.

[11]  C. Cingi,et al.  Antileukotrienes in Upper Airway Inflammatory Diseases , 2015, Current Allergy and Asthma Reports.

[12]  V. Kirtsreesakul,et al.  Clinical Efficacy of Nasal Steroids on Nonallergic Rhinitis and the Associated Inflammatory Cell Phenotypes , 2015, American journal of rhinology & allergy.

[13]  A. Fetoni,et al.  Nasal lavage levels of granulocyte‐macrophage colony‐stimulating factor and chronic nasal hypereosinophilia , 2015, International forum of allergy & rhinology.

[14]  A. Fetoni,et al.  Nasal fluid release of eotaxin‐3 and eotaxin‐2 in persistent sinonasal eosinophilic inflammation , 2014, International forum of allergy & rhinology.

[15]  P. Gibson,et al.  Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. , 2014, Allergy and asthma proceedings.

[16]  G. Devouassoux,et al.  Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities , 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

[17]  M. Kaliner,et al.  Nonallergic rhinitis , 2013 .

[18]  Z. Yazıcı,et al.  Effect of montelukast on quality of life in subjects with nasal polyposis accompanying bronchial asthma. , 2011, Kulak burun bogaz ihtisas dergisi : KBB = Journal of ear, nose, and throat.

[19]  G. Paludetti,et al.  Nasal lavage CCL24 levels correlate with eosinophils trafficking and symptoms in chronic sino-nasal eosinophilic inflammation. , 2011, Rhinology.

[20]  J. Mullol,et al.  Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. , 2010, Journal of biological regulators and homeostatic agents.

[21]  E. Scarano,et al.  Eosinophilic fungal rhinosinusitis due to the unusual pathogen Curvularia inaequalis , 2010, Mycoses.

[22]  H. Isildak,et al.  Evaluation of nasal cytology in subjects with chronic rhinitis: a 7-year study. , 2009, American journal of otolaryngology.

[23]  G. Ciprandi,et al.  Non-Allergic Rhinitis with Eosinophils and Mast Cells Constitutes a New Severe Nasal Disorder , 2008, International journal of immunopathology and pharmacology.

[24]  J. Denburg,et al.  The effects of montelukast on tissue inflammatory and bone marrow responses in murine experimental allergic rhinitis: interaction with interleukin‐5 deficiency , 2007, Immunology.

[25]  S. Jang,et al.  Responsiveness to montelukast is associated with bronchial hyperresponsiveness and total immunoglobulin E but not polymorphisms in the leukotriene C4 synthase and cysteinyl leukotriene receptor 1 genes in Korean children with exercise‐induced asthma (EIA) , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  V. Lund,et al.  The Lund-Mackay staging system for chronic rhinosinusitis: How is it used and what does it predict? , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[27]  G. Marshall,et al.  Montelukast in the management of allergic rhinitis , 2007, Therapeutics and clinical risk management.

[28]  U. Mitzdorf,et al.  Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials , 2007, BMC medicine.

[29]  C. Bachert,et al.  Rhinosinusitis: Developing guidance for clinical trials. , 2006, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[30]  C. Bachert,et al.  Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. , 2006, Respiratory medicine.

[31]  P. Keith,et al.  Nonallergic rhinitis with eosinophilia syndrome , 2006, Current allergy and asthma reports.

[32]  William H. Yang,et al.  Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[33]  T. Reiss,et al.  The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis , 2004, Current medical research and opinion.

[34]  E. Meltzer,et al.  Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period , 2003, Allergy.

[35]  P. Keith,et al.  Repeatability and validity of cell and fluid‐phase measurements in nasal fluid: a comparison of two methods of nasal lavage , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[36]  M. Ichinose,et al.  Leukotriene Receptor Antagonists and Antiallergy Drugs. , 2017, Handbook of experimental pharmacology.

[37]  L. Vangerven,et al.  report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis , 2017 .

[38]  A. Fetoni,et al.  Role of inflammation in non-allergic rhinitis. , 2014, Rhinology.

[39]  M. Kaliner,et al.  Chapter 14: Nonallergic rhinitis. , 2013, American journal of rhinology & allergy.

[40]  R. B. Langdon,et al.  Montelukast in the Treatment of Allergic Rhinitis , 2012, Drugs.